Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Intel’s Standstill With Altera Expires in June; Hostile Bid Could Follow

Sources said Intel offered $54 a share after reviewing Altera’s non-public information, but the bid was rejected.

Justin Doly / Getty

Intel signed a standstill agreement earlier this year with Altera that expires on June 1, giving the world’s largest chip maker the option to launch a hostile bid after that, according to sources familiar with the matter.

The agreement, disclosed to Reuters by the sources this week, explains why Intel has refrained from launching a tender offer for Altera’s shares once their negotiations broke down. It also underscores the risk Altera faces of such a hostile bid.

Earlier this month, Altera rejected an unsolicited $54 per share offer from Intel following months of negotiations, the sources said, asking not to be identified discussing confidential information. They said Altera agreed to engage in these talks on the basis that Intel would not go public with any offer until June.

In February, Intel discussed offering $58 per share for Altera, based on publicly available information it reviewed at the time, according to the people. After signing a non-disclosure agreement and combing through non-public information, including the company’s outlook, it ended up revising down its offer, they said. Last week, Altera posted a sequential 9 percent decline in revenue for the first quarter and said it also expects weakness in its second-quarter guidance, particularly around its wireless business.

It is unclear whether Intel would take its proposal directly to shareholders, the sources said, but it remains an option available to it.

Intel and Altera both declined to comment.

The acquisition of Altera, which makes programmable chips widely used in cellphone towers and industrial applications and by the military, would underscore Intel Chief Executive Officer Brian Krzanich’s determination to expand into new markets as the personal computer industry loses steam.

TIG Advisors, an investment firm that holds shares in Altera, challenged a nomination to the company’s board of directors on Monday over Altera’s refusal to engage with Intel about a potential merger.

(Reporting by Nadia Damouni; Additional reporting by Liana Baker; Editing by Ted Botha)

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh